Poxel S.A. (EPA:POXEL)
0.4190
-0.0045 (-1.06%)
Oct 7, 2025, 4:45 PM CET
Poxel Revenue
Poxel had revenue of 1.16M EUR in the half year ending June 30, 2024, with 1,300.00% growth. This brings the company's revenue in the last twelve months to 2.19M, up 41.53% year-over-year. In the year 2023, Poxel had annual revenue of 1.98M with 193.92% growth.
Revenue (ttm)
2.19M
Revenue Growth
+41.53%
P/S Ratio
10.06
Revenue / Employee
364.67K
Employees
6
Market Cap
22.00M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 1.98M | 1.31M | 193.92% |
Dec 31, 2022 | 674.00K | -12.72M | -94.97% |
Dec 31, 2021 | 13.40M | 6.59M | 96.84% |
Dec 31, 2020 | 6.81M | -19.75M | -74.37% |
Dec 31, 2019 | 26.56M | -35.82M | -57.43% |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2014 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
EssilorLuxottica Société anonyme | 27.24B |
Sanofi | 45.74B |
Sartorius Stedim Biotech | 2.90B |
bioMérieux | 4.12B |
Eurofins Scientific SE | 7.14B |
Ipsen | 3.76B |
ABIVAX Société Anonyme | 6.02M |
Virbac | 1.43B |
Poxel News
- 2 months ago - Following the Filing for the Opening of Reorganization Proceedings, Poxel Announces Changes to Its Corporate Governance - Business Wire
- 2 months ago - Poxel Provides Update on Negotiations with Creditors and Announces Filing of Reorganization Proceedings, Upcoming Change of Corporate Governance and Suspension of Trading - Business Wire
- 3 months ago - Poxel Announces Postponement of its Annual General Meeting and Provides a Corporate Update - Business Wire
- 3 months ago - Poxel SA: New Scientific Presentations by Key Opinion Leaders to Further Highlight the Therapeutic Potential of Imeglimin at ADA 2025, the Leading Diabetes Conference - Business Wire
- 4 months ago - New Clinical and Scientific Data on TWYMEEG® to be Presented at the 68th Annual Meeting of the Japan Diabetes Society - Benzinga
- 4 months ago - Poxel Announces Positive Preclinical Data for PXL065 in Hypertrophic Cardiomyopathy To Be Presented at the ESC Congress 2025 - Business Wire
- 5 months ago - Poxel S.A. reports Q1 results - Seeking Alpha
- 5 months ago - Poxel Reports Consolidated Revenue for the First Quarter 2025 and Provides Corporate Update - Business Wire